KRAS and neoplasm: Specifically, KRAS G12D DNA from LS174T was almost 60 times less abundant than G13D DNA from LoVo (958 vs 56,359 copies/mL; compare J and R) in culture supernatants and, viceversa, it was approximately 8 times more abundant (compare L and T; 139 vs 17 c/mL) in blood, demonstrating a 500-fold difference in the ability of the two cell lines to generate accumulation of RAS ctDNA in cell supernatants vs blood of tumor-xenotransplanted mice.